AMPH
Price
$22.96
Change
-$0.22 (-0.95%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
986.03M
62 days until earnings call
Intraday BUY SELL Signals
ZTS
Price
$73.57
Change
-$2.24 (-2.95%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
31.33B
64 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMPH vs ZTS

AMPH vs ZTS Comparison Chart in %
View a ticker or compare two or three
VS
AMPH vs. ZTS commentary
Sep 08, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a Hold and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2026
Stock price -- (AMPH: $23.18 vs. ZTS: $75.81)
Brand notoriety: AMPH: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMPH: 150% vs. ZTS: 72%
Market capitalization -- AMPH: $986.03M vs. ZTS: $31.33B
AMPH [@Pharmaceuticals: Generic] is valued at $986.03M. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $31.33B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).

  • AMPH’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 2 green, 3 red.
According to our system of comparison, both AMPH and ZTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 6 bullish TA indicator(s).

  • AMPH’s TA Score: 3 bullish, 4 bearish.
  • ZTS’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than AMPH.

Price Growth

AMPH (@Pharmaceuticals: Generic) experienced а +5.32% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -1.98% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.98%. For the same industry, the average monthly price growth was -1.38%, and the average quarterly price growth was +34.77%.

Reported Earning Dates

AMPH is expected to report earnings on Nov 09, 2026.

ZTS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.98% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($31.3B) has a higher market cap than AMPH($986M). AMPH has higher P/E ratio than ZTS: AMPH (13.72) vs ZTS (12.37). AMPH YTD gains are higher at: -13.443 vs. ZTS (-38.803). ZTS has higher annual earnings (EBITDA): 4.02B vs. AMPH (193M). ZTS has more cash in the bank: 1.67B vs. AMPH (290M). AMPH has less debt than ZTS: AMPH (688M) vs ZTS (9.24B). ZTS has higher revenues than AMPH: ZTS (9.53B) vs AMPH (730M).
AMPHZTSAMPH / ZTS
Capitalization986M31.3B3%
EBITDA193M4.02B5%
Gain YTD-13.443-38.80335%
P/E Ratio13.7212.37111%
Revenue730M9.53B8%
Total Cash290M1.67B17%
Total Debt688M9.24B7%
FUNDAMENTALS RATINGS
AMPH vs ZTS: Fundamental Ratings
AMPH
ZTS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
10
Undervalued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
6918
PRICE GROWTH RATING
1..100
4464
P/E GROWTH RATING
1..100
2194
SEASONALITY SCORE
1..100
5045

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZTS's Valuation (10) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AMPH (55) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew somewhat faster than AMPH’s over the last 12 months.

AMPH's Profit vs Risk Rating (94) in the Pharmaceuticals Other industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's SMR Rating (18) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AMPH (69) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew somewhat faster than AMPH’s over the last 12 months.

AMPH's Price Growth Rating (44) in the Pharmaceuticals Other industry is in the same range as ZTS (64) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew similarly to ZTS’s over the last 12 months.

AMPH's P/E Growth Rating (21) in the Pharmaceuticals Other industry is significantly better than the same rating for ZTS (94) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew significantly faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHZTS
RSI
ODDS (%)
Bearish Trend 5 days ago
61%
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
67%
Bearish Trend 5 days ago
70%
Momentum
ODDS (%)
Bullish Trend 5 days ago
73%
Bearish Trend 5 days ago
65%
MACD
ODDS (%)
N/A
Bullish Trend 5 days ago
64%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
79%
Bearish Trend 5 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
53%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 14 days ago
51%
Declines
ODDS (%)
Bearish Trend 16 days ago
69%
N/A
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
71%
Bullish Trend 5 days ago
64%
Aroon
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
AMPH
Daily Signal:
Gain/Loss:
ZTS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JDINX67.370.34
+0.51%
Janus Henderson Overseas N
JEEDX19.73-0.04
-0.20%
JHancock Infrastructure R6
NFJEX12.54-0.05
-0.40%
Virtus NFJ Dividend Value Inst
RIRBX84.26-0.36
-0.43%
American Funds Capital Inc Bldr R-2
BIPSX51.66-0.28
-0.54%
ProFunds Biotechnology UltraSector Svc